ArticleEuropean journal of nuclear medicine and molecular imaging2023

FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective.

Antoine Verger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.